by sfrazee | Aug 14, 2024 | News Article, Uncategorized
By Prof. Casey B. Mulligan and Em. Prof. Tomas J. Philipson Democrats don’t understand healthcare markets. We agree with your editorial “Biden Does a Stealth Medicare Rewrite” (Aug. 6) on the Inflation Reduction Act’s harm to the Medicare drug program. Two years ago,...
by sfrazee | Apr 25, 2024 | White Papers
The rapid emergence of vaccines and therapeutics in response to the onset of the coronavirus (COVID-19) pandemic demonstrated the value of medical innovation. These advances not only led to enhanced patient welfare by reducing the disease’s mortality and morbidity but...
by sfrazee | Jun 10, 2023 | White Papers
This policy brief reviews the evidence on the health and cost impacts of multi-cancer early detection (MCED) tests, and the implications for proposed legislation to enhance their utilization in Medicare. We find that the evidence base suggests that MCED screening...
by sfrazee | Dec 23, 2022 | White Papers
This Policy Brief analyzes the impact of The Inflation Reduction Act (IRA) on generic and biosimilar competition. We first review the large savings that generic and biosimilar competition entails in the U.S., which is threatened by competitors’ uncertain investments....
by sfrazee | Nov 1, 2022 | Uncategorized, White Papers
This policy brief contains a set of recommendations for improving access and competition in the state of Wisconsin’s health care system. These recommendations are based on how current state and federal reforms apply to Wisconsin. The brief is focused on four main...
